GLPwatch

Preservation of the blood brain barrier and cortical neuronal tissue by liraglutide, a long acting glucagon-like-1 analogue, after experimental traumatic brain injury.

PLoS One · 2015

Last updated 2026-05-28

In a study on rats with moderate to severe brain injuries, twice-daily injections of the GLP-1 drug liraglutide (200 micrograms per kilogram) for two days reduced brain swelling and tissue damage in the injured area. The treatment also helped preserve the blood-brain barrier and improved movement-related functions 48 hours after injury, though it did not reduce damage in the thalamus.

AI summary of the abstract below.

JournalPLoS One, 2015
Citations45
Relative citation ratio1.81
NIH percentile70
Molecules liraglutide

Abstract

Cerebral edema is a common complication following moderate and severe traumatic brain injury (TBI), and a significant risk factor for development of neuronal death and deterioration of neurological outcome. To this date, medical approaches that effectively alleviate cerebral edema and neuronal death after TBI are not available. Glucagon-like peptide-1 (GLP-1) has anti-inflammatory properties on cerebral endothelium and exerts neuroprotective effects. Here, we investigated the effects of GLP-1 on secondary injury after moderate and severe TBI. Male Sprague Dawley rats were subjected either to TBI by Controlled Cortical Impact (CCI) or sham surgery. After surgery, vehicle or a GLP-1 analogue, Liraglutide, were administered subcutaneously twice daily for two days. Treatment with Liraglutide (200 μg/kg) significantly reduced cerebral edema in pericontusional regions and improved sensorimotor function 48 hours after CCI. The integrity of the blood-brain barrier was markedly preserved in Liraglutide treated animals, as determined by cerebral extravasation of Evans blue conjugated albumin. Furthermore, Liraglutide reduced cortical tissue loss, but did not affect tissue loss and delayed neuronal death in the thalamus on day 7 post injury. Together, our data suggest that the GLP-1 pathway might be a promising target in the therapy of cerebral edema and cortical neuronal injury after moderate and severe TBI.

Verbatim abstract via PubMed 25822252 ↗

Related research